EDGAR Filing Documents for 0001171843-22-004066

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:

SEC Accession No. 0001171843-22-004066

Filing Date

2022-06-01

Accepted

2022-06-01 12:08:01

Documents

Document Format Files

Seq	Description	Document	Type	Size
1	FORM DEFA14A	defa14a_060122.htm	DEFA14A	27660
2	GRAPHIC	logo.jpg	GRAPHIC	3552
3	GRAPHIC	defa14a_01.jpg	GRAPHIC	62001
4	GRAPHIC	defa14a_02.jpg	GRAPHIC	60314
5	GRAPHIC	defa14a_03.jpg	GRAPHIC	88088
6	GRAPHIC	defa14a_04.jpg	GRAPHIC	65702
7	GRAPHIC	defa14a_05.jpg	GRAPHIC	72069
8	GRAPHIC	defa14a_06.jpg	GRAPHIC	71703
9	GRAPHIC	defa14a_07.jpg	GRAPHIC	58167
10	GRAPHIC	defa14a_08.jpg	GRAPHIC	80084
11	GRAPHIC	defa14a_09.jpg	GRAPHIC	96870
12	GRAPHIC	defa14a_10.jpg	GRAPHIC	93595
13	GRAPHIC	defa14a_11.jpg	GRAPHIC	72532
14	GRAPHIC	defa14a_12.jpg	GRAPHIC	68362
	Complete submission text file	0001171843-22-004066.txt		1260605

Mailing Address 32 WIGGINS AVENUE BEDFORD MA 01730

Business Address 32 WIGGINS AVENUE BEDFORD MA 01730 (781) 457-9000

Anika Therapeutics, Inc. (Filer) CIK: 0000898437 (see all company filings)